Foghorn Therapeutics, Inc. (FHTX) has disclosed a new risk, in the Regulation category.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Foghorn Therapeutics, Inc. faces a significant business risk that could impact its operations and financial stability, as highlighted in the risk factor titled ‘2121Item’. This risk factor suggests potential vulnerabilities that may arise from external or internal challenges, which could hinder the company’s ability to achieve its strategic objectives. The implications of such risks could lead to operational disruptions, financial losses, or reputational damage, thereby affecting investor confidence and market performance. Stakeholders should closely monitor these developments to assess the potential impact on Foghorn Therapeutics’ future prospects.
The average FHTX stock price target is $8.67, implying 65.14% upside potential.
To learn more about Foghorn Therapeutics, Inc.’s risk factors, click here.